DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Precision Wires India schedules EGM to approve ₹150 crore CCD issue

scanx.trade 16 hrs ago·5 Sept 2026, 2:48 am

Precision Wires India has announced an Extraordinary General Meeting (EGM) to seek shareholder approval for issuing up to ₹150 crore in compulsorily convertible debentures (CCDs). This debt instrument will convert into equity shares after a set period, allowing the company to raise fresh capital without immediately diluting ownership.

For investors, this move signals the company's intent to fund expansion plans, potentially boosting future growth. It also indicates financial flexibility, as CCDs provide a hybrid funding option. However, the conversion terms and the use of proceeds will determine the long-term impact on the stock.

Investors should monitor the company's future announcements regarding the use of these funds and the timeline for the CCD conversion. This will help assess whether the capital infusion will drive value creation or increase leverage.